|
End-of-day quote
Taiwan S.E.
04/09/2026
|
5-day change | 1st Jan Change | ||
| 1,310.00 TWD | -2.96% |
|
-15.21% | +209.18% |
| 08-31 | PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10% | MT |
| 08-29 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 542,906 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 212.32% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 516,382 | 508,178 | 542,906 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 236.57% | -1.59% | 6.83% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 49.4x | 31.1x | 21.4x |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 12.3x | 9.71x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 0x | 0.5x | 0.5x |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 19.2x | 13.6x | 10.1x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 18.2x | 12.7x | 10.1x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 37x | 27.6x | 32.7x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 39.9x | 26.9x | 33.4x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 73.2x | 49.7x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 1.37% | 2.01% | - |
| Dividend per Share 2 | - | - | - | 0.8936 | 1.352 | 4 | 2.35 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | 0.31% | 0.18% | - |
| EPS 2 | -8.773 | -3.932 | -1.568 | 7.214 | 12.25 | 26.51 | 42.13 | 61.25 |
| Distribution rate | - | - | - | 12.4% | 11% | 15.1% | 5.58% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 28,328 | 40,060 | 53,837 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 13,965 | 18,433 | 16,591 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 12,929 | 18,909 | 16,243 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 11,022 | 17,690 | 25,880 |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -26,524 | -34,728 | - |
| Reference price 2 | 238.02 | 387.49 | 281.07 | 499.59 | 423.70 | 1,310.00 | 1,310.00 | 1,310.00 |
| Nbr of stocks (in thousands) | 327,980 | 371,210 | 407,644 | 409,783 | 410,264 | 414,432 | - | - |
| Announcement Date | 3/2/22 A | 3/1/23 A | 2/27/24 A | 2/26/25 A | 3/3/26 A | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 49.41x | 18.23x | 36.98x | 0.31% | 17.16B | |
| 20.25x | 7.04x | 14.2x | 1.45% | 67.98B | |
| 36.9x | 9.64x | 29.44x | 0.04% | 64.94B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.85x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.69x | 6.35x | 16.48x | -.--% | 25.74B | |
| 27.41x | 5.13x | 17.06x | -.--% | 20.09B | |
| 1289.22x | 37.23x | 812.54x | -.--% | 14.92B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| -15.07x | 3394.08x | -17.35x | -.--% | 14.04B | |
| Average | 136.29x | 350.42x | 84.24x | 0.18% | 29.31B | |
| Weighted average by Cap. | 77.36x | 172.47x | 48.29x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
